Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Valerina Changarathil

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

November 15, 2024
Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.
Read Transcript

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
March 14, 2025

$1.4 million boost for SA medical research

South Australian medical research will receive a $1.4 million cash injection, as a direct result of a major investment and philanthropy conference held in Adelaide.

Read More
Anthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. AP
May 19, 2025

Why ‘The Mooch’ thinks Trump is more dangerous this time around

Anthony Scaramucci says Trump has fewer constraints on his worst instincts in his second administration. But he still gets bored easily.

Read More
Image caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn Licht
May 19, 2025

My biggest mistake: Anthony Scaramucci on what makes Donald Trump tick

On Elon Musk, money and the White House, fast-talking Wall Street hedge fund manager and former Trump communications director Anthony Scaramucci tells it as he sees it.

Read More
A bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFP
May 19, 2025

Bitcoin ‘on track’ for $US200,000: Anthony Scaramucci

Bitcoin could hit as much as $US200,000 ($311,000) by the end of this year, fuelled by surging inflows into exchange-traded funds and Donald Trump’s erratic policymaking.

Read More
Anthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn Licht
May 19, 2025

‘The Mooch’ says Trump will have to cut China tariffs below 10pc

Scaramucci, who is best known as The Mooch, is the first big-name global investor to be confirmed for the Sohn Hearts & Minds conference in Sydney in November.

Read More
December 19, 2024

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
Nick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben SearcyNick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben SearcyNick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben SearcyNick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben Searcy
November 20, 2024

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
Wall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben SearcyWall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben SearcyWall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben SearcyWall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben Searcy
November 17, 2024

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
Ellerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy PhotographyEllerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy PhotographyEllerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy PhotographyEllerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy Photography
November 15, 2024

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15, 2024

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
Markets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFPMarkets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFPMarkets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFPMarkets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFP
November 15, 2024

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15, 2024

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15, 2024

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
Mike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/Bloomberg
November 9, 2024

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍
November 6, 2024

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.